

EVALUATING NEUROPROTECTIVE EFFECTS OF ASCORBIC ACID AGAINST 3-NITROPROPIONIC ACID INDUCED HUNTINGTON'S DISEASE IN RATS: POSSIBLE INVOLVEMENT OF GABAA RECEPTORS

Dharmender Jaglan & Chanpreet Singh Bindra

Chandigarh College of Pharmacy, Landran, Mohali, Punjab, India

Received: 03 Feb 2018

Accepted: 09 Feb 2018

Published: 21 Feb 2018

ABSTRACT

Huntington's disease (HD) is a genetic, progressive and fatal neurodegenerative disorder characterized by the gradual development of involuntary muscle movements and associated with severe degeneration of basal ganglia neurons (Paulsen et al., 2008; Raymond et al., 2011). An expanded unstable CAG trinucleotide repeat within the coding region of the HD gene has been identified as the genetic mutation responsible for the disease (HD Collaborative Research Group, 1993). The progression of disease is generally late-onset and characterized by psychiatric, cognitive and motor disturbances (Shannon, 2011) due to progressive neurodegeneration in the cerebral cortex, hippocampus, striatum and basal ganglia (Bates, 2004; Hart et al., 2013). In some cases, involuntary movements may be prominent even in the early stages. As documented, first signs of HD are behavioral disturbances and learning difficulties (Paulsen & Canybeare, 2005; Stout et al., 2012).

KEYWORDS: *Disease, Generally Late-Onset, Characterized By Psychiatric Cognitive*

INTRODUCTION

Huntingtin is proteolysed by caspase-1 and caspase-3 (Goldberg et al., 1997; Wellington et al., 2000). In HD models and in presymptomatic and early symptomatic stages of HD patients caspase-1 and caspase-3 gene expression is transcriptionally up-regulated (Chen et al., 2000). This leads to an increase of caspase-mediated cleavage of huntingtin and increases the generation of N-terminal huntingtin fragments that are prone to form toxic aggregates in neurons (Hackam et al., 1998; Wellington et al., 2000), while depleting wild type huntingtin (Kiechle et al., 2002). It appears that some features of HD result from the depletion of huntingtin protein function, whereas the consequent N-terminal toxic fragments themselves may exert toxic effects on the cell by transcriptional disruption of other genes (Nucifora et al., 2001; Hickey et al., 2003; Landles et al., 2004).

HD symptoms and signs begin insidiously and onset usually occurs during the fourth or fifth decade of life with a mean survival of 15 to 20 years after disease onset (Vonsattel et al., 2004). However, the age of disease onset can vary from childhood until old age and can be correlated with the length of the polyglutamine repeat in the huntingtin gene (Raymond et al., 2011). In patients with juvenile-onset HD, with disease onset before the age of 20 years, the signs and symptoms are somewhat different; they include bradykinesia, rigidity and dystonia while chorea can be completely absent. Involuntary movements can take the form of tremor or myoclonus and affected children often develop epileptic seizures (Rubinsztein, 2002; Vonsattel et al., 2004). As to epidemiology, the incidence and prevalence of HD varies between ethnic

groups. The disorder is more common among European populations with a prevalence of almost 1 in 10,000, in comparison with Japanese and African populations, where the prevalence may be less than 1 in 1,000,000 (Vonsattel *et al.*, 1998; Vonsattel *et al.*, 2004).

3-Nitropropionic acid (3-NP) is a natural environmental toxin obtained from various plants and fungi which can induce HD (Coles *et al.*, 1979; Kumar and Kumar, 2008). 3-NP is a non-competitive inhibitor of mitochondrial succinate dehydrogenases (SDH) in the brain (Gould *et al.*, 1985; Alexi *et al.*, 1998; Brouillet *et al.*, 1998), an enzyme located in the mitochondrial inner membrane and causes rapid suppression of energy metabolism in the brain (Beal, 1994; Guyot *et al.*, 1997). This phenomenon results in the release of excitotoxic neuromediators induces a reduction in the ATP production and gives rise to free radicals (Tabrizi *et al.*, 2000; Perez-Severino *et al.*, 2002). Both, nitric oxide and reactive oxygen species produced by 3-NP disturbs glutathione redox cycle (Beal, 1998; Tunez *et al.*, 2004) and causes oxidative stress. It has also been reported that 3-NP administration results in striatal lesions similar to that of HD brains (Brouillet *et al.*, 1999).

Vitamin C (Ascorbic acid) is the most important vitamin in fruits and vegetables, and has been regarded as the most potent natural antioxidant (Vissers *et al.*, 2011). Although, most of the higher animals can synthesize vitamin C in their liver or kidneys, but in humans, the terminal enzyme in its synthetic pathway is absent and thus, vitamin C has become an essential dietary component for human survival (Vissers *et al.*, 2011). Ascorbic acid is a versatile water soluble radical scavenger widely distributed in aerobic organisms that play a central role in the protection of cellular components against oxidative damage by free radicals and oxidants that are involved in the development and exacerbation of a multitude of chronic diseases (Ozkanlar & Akcay, 2012; Myung *et al.*, 2013). Studies have reported that Ascorbic acid being an endogenous redox agent is highly concentrated in the various regions of the CNS and is found to be accumulated in high concentration in neurons and glial cell (Harrison *et al.*, 2009). Ascorbic acid serves as a neuromodulator in normal brain functioning and as a neuroprotective agent in various conditions of oxidative stress (Grunewald, 1993). Previous studies have indicated that ascorbic acid is cardio-protective, hepatoprotective, anticonvulsant as well as reno-protective in nature (Korkmaz *et al.*, 2009).

γ -aminobutyric acid (GABA) has been found to play an important role in the basal ganglia function (Graybiel *et al.*, 1990). The GABA system is the major inhibitory system in the rat brain (Wallace *et al.*, 2007). The evidences suggest that GABA may play a supplementary role in brain diseases by modulating dopamine and serotonin. A GABAergic deficit is particularly apparent in insomnia, anxiety disorders, epilepsy, and schizophrenia (Wallace *et al.*, 2001; Scheffer *et al.*, 2003). The caudate nucleus and putamen of the brain have high levels of GABA (Graybiel *et al.*, 1983).

The substantianigra (SN) is a major division of the basal ganglia, a group of subcortical nuclei involved in a variety of functions including movement, memory and cognition (Celada *et al.*, 1999). Most of the effects of GABA in the SN are mediated through postsynaptic GABA-A receptors, which cause an increase in chloride conductance that underlies fast inhibitory postsynaptic potentials (Pirker *et al.*, 2000; Schwarzer *et al.*, 2001). Dysfunctions of GABAergic transmission in the SN have been implicated in a variety of diseases and their models. Excitotoxic lesions of the striatum leads to a loss of striatonigral GABAergic neurons and to changes in striatal targets that are similar to the changes that occur in Huntington's disease and, as such, have been used as models of this disease (Glass *et al.*, 2000). Furthermore, functional changes have been reported in nigral GABA-A receptors in an in vitro expression system following excitotoxic

lesions of the striatum in the rat (Sanna *et al.*, 1998). Inappropriate disinhibition of basal ganglia targets have been proposed to underlie the abnormal involuntary movements associated with Huntington's disease (Albin *et al.*, 1989; DeLong, 1990).

Bicuculline acts as a competitive antagonist at GABA_A receptors (Andrews and Johnston, 1979). This evidence is supported by functional studies. Single channel studies have shown that bicuculline reduces GABA activated conductance by reducing both channel opening times and opening frequency (Macdonald *et al.*, 1989). In this study, bicuculline is employed as an antagonist to confirm the involvement of GABA receptor.

There has been a lot of research at various levels involving GABA-A receptors in HD. But, direct involvement of Ascorbic acid in HD and its action through GABA-A receptor has not been studied. So, present study is designed to investigate the activation of GABA-A receptor as a potential molecular mechanism in Ascorbic acid-mediated protection against 3-NP induced HD.

MATERIALS AND METHODS

Experimental Animals

Male wistar rats (procured from National Institute of Pharmaceutical Education and Research, Mohali) maintained in the central animal house of the facility of Chandigarh College of Pharmacy, Landran, Mohali, Punjab and weighing between 200 and 250g of were used. The animals were kept under standard conditions of light and dark cycle with food and water ad libitum in plastic cages with husk bedding. All the experiments were carried out between 09:00 and 15:00 hr in semi- sound proof laboratory conditions. The protocol was approved by the Institutional Animal Ethics Committee vide no (1201/a/08/CPCSEA) and carried out in accordance with the Indian National Academy Guidelines for the use and care of animals. Adequate measures were taken to minimize the pain and discomfort to the animals. The care of the animals was carried out as per the guidelines of the Committee for the Purpose of Control and Supervision of Experimental Animals (CPCSEA), Ministry of Environment and Forests, Government of India.

Drugs and Chemicals

All chemicals and biochemical reagents of analytical grade and highest purity were used. The following agents were used in the present study: 3-Nitropropionic acid (Sigma-Aldrich Corporation, India) was diluted with saline (adjusted pH 7.4 with NaOH) and administered intraperitoneally (*i.p.*), Ascorbic Acid (LobaChemiePvt.LTD.), Bicuculline (Cayman chemicals company) was used as an antagonist of GABA receptors and Mifepristone (1mg/kg, *i.p.*) was used as progesterone antagonist. DMSO and Olive Oil was used to Bicuculline and Mifepristone.

Animal Model for Huntington's Disease

3-nitropropionic acid (10mg/kg) was administered intraperitoneally (*i.p.*) once daily for a period of 14 days to induce the symptoms of HD (Kumar & Kumar, 2009). 3-NP injection was freshly prepared in normal saline (0.5 ml of normal saline per 100gm of animal weight) before administration. Only rats with positive behavioral effects were included in the study. All animals were trained for 4 days before administration. All the behavioral parameters were observed before drug administration and 24 hrs after first dose and 24 hrs after the last dose, that on the 15th day after the start of 3-NP treatment.

Measurement of Body Weight

Body weight was noted in the first and last days of the experiment. Percentage change in body weight was calculated in comparison with an initial body weight on the first day of experimentation.

BEHAVIOURAL ASSESSMENTS

- **Elevated Plus Maze Paradigm**

Elevated plus maze is used to test learning and memory (Kumar *et al.*, 2010). The elevated plus maze consisted of two opposite open arms crossed with two closed arms of the same dimensions. The arms are connected to a central square. Acquisition of memory was assessed on the day 1st before initiating 3-NP treatment in the control group. Rats were placed individually at one end of an open arm facing away from the central square. The time taken by the animal to move from the open arm into the closed arm is recorded as the initial transfer latency. The animals were allowed to explore the maze for 30sec after recording the initial latency and then returned to its home cage. If the animal did not enter an enclosed arm within 90sec, it was gently pushed into the enclosed arm and the transfer latency is assigned as 90sec. Retention of memory was assessed by similarly placing a rat on an open arm and noting the retention latency 24 hr (day 2) and 4 days (day 5) after the initial transfer latency (ITL). These times were referred to as the first retention transfer latency and second retention transfer latency, respectively (Kulkarni *et al.*, 1993).

- **Morris Water Maze (Spatial Navigation Task)**

The acquisition and retention of the spatial task were examined using the Morris water maze. Animals were trained to swim to a platform in a circular pool located in a test room. The pool was filled with water (24± 2c) to a depth of 40 cm. A movable circular platform, 9 cm in diameter and mounted on a column was placed in the pool 1 cm above the water level (visible platform) for the maze acquisition test. Another movable platform, 9 cm in diameter and mounted on a column, was placed in the pool 1 cm below the water level (hidden platform) for the maze retention test.

Maze Acquisition Test (Training)

Animals received a training session consisting of 4 trails in day for four days before 3-NP administration. In all 4 days, the starting positions were different. The latency to find the escape platform was recorded up to a maximum of 2 min. The visible platform was fixed in the centre of one of the 4 quadrants and remained there throughout the experiment. The time taken by a rat to reach the platform on the fourth day was recorded as the initial acquisition latency.

Maze Retention Test (Testing For Retention of the Learned Task)

Following 24 h (day 5) and 14 days (day 15) after the initial acquisition latency (IAL), rats were randomly released at any edges facing the wall of the pool and tested for the retention of the response. The time taken to reach the hidden platform on days 5 and 15 following initiation of 3-NP treatment was recorded and termed as the first retention latency and second retention latency, respectively (Frautschy *et al.*, 2001).

- **Assessment of Gross Loco motor Activity by Using Act photometer**

The locomotor activity was monitored using Actophotometer on 1st, 5th, 15th, day of 3-NP administered and Ascorbic Acid treated groups (Kumar *et al.*, 2010). The horizontal motor activity was detected by two perpendicular arrays

of 15 infrared beams located 2.5 cm above the floor of the testing area. Each interruption of a beam on the x or y-axis generated an electric impulse, which was presented on a digital counter. Similarly, the vertical motor activity was recorded using the additional row of infrared sensors located 12 cm above the floor. Each animal was observed over a period of 5 min and values expressed as counts per 5 min. The apparatus was placed in a darkened, light and sound attenuated and ventilated testing room (Reddy *et al.*, 1998)

- **Assessment of Grip Strength Activity by Using Rotarod**

All animals were evaluated for motor ability and balance by using the rotarod on 1st, 5th, and 15th day of treatment (Kumar *et al.*, 2010). The rats were given a prior training session before initialization of any therapy to acclimate them to Rotarod apparatus. Rats were placed on the rotating rod with a diameter of 7 cm (speed 25 rpm). The length of time in the rod was taken as the measure of competency. The cutoff time as 180 sec and each rat performed three separate trials. The average result was recorded (Kulkarni, 1999).

- **Assessment of the Biochemical Parameters**

Biochemical tests were carried out after the last behavioural test.

- **Tissue Preparation**

Animals were sacrificed by decapitation and the brains were removed and rinsed with ice-cold isotonic saline. Brain tissue samples were then homogenized (10 times (w/v) with ice –cold 0.1M phosphate buffer (ph 7.4). the homogenate was centrifuged at 10,000xg for 15 min and aliquots of supernatant were separated and used for biochemical experiments.

- **Thiobarbituric Acid Reactive Substances (TBARS)**

The quantitative measurement of thiobarbituric acid reactive substances (TBARS), an index of lipid peroxidation in renal tissue was performed according to method of Nichans and Samuelson, (1968). In this method, malondialdehyde and other TBARS was measured by their reactivity with thiobarbituric acid in an acidic condition to generate pink coloured chromophore which will be measured spectrophotometrically at 535 nm. To 1.0 mL of tissue homogenate, 2 mL of trichloroacetic acid-thiobarbituric acid-hydrochloric acid (TCA-TBA-HCl) reagent will be added and mixed thoroughly. The mixture will be kept in a boiling water bath for 15 min. After cooling the tubes will be centrifuged at 10000 g for 10 min. The colour developed in the supernatant will be measured at 535 nm against blank reagent. A series of standard solutions of tetra methoxy propane in the concentration of 1 to 10 nM will be treated in the similar manner. Values will be expressed as nano moles per mg of protein.

PREPARATION OF REAGENTS

Preparation of 0.37% Thiobarbituric acid (TBA) Solution

0.37g of thiobarbituric acid was dissolved in 100ml distilled water.

Preparation of 15% Trichloroacetic acid (TCA) Solution

15 ml of TCA was dissolved in 100ml distilled water.

Preparation of 0.25N of Hydrochloric acid (HCL) Solution

2.23 ml of HCL was taken in measuring cylinder and volume was made upto 1000 ml with distilled water.

Preparation of 1nM 1,1,3,3-Tetraethoxy Propane

0.82 ml of standard 1,1,3,3-tetraethoxy propane was diluted to 5 ml with diluted water to make 1M solution. 1ml of this solution was further diluted to 10 ml with distilled water and this diluted process was further repeated for eight times to get 1nM 1,1,3,3-Tetraethoxy propane

Reduced Glutathione (GSH) Level

The whole brain level was estimated by method of Beutler et al, (1963). The supernatant of tissue homogenate were mixed with trichloroacetic acid (10% w/v) in 1:1 ratio. The tubes were centrifuged at 1000g for 10 min at 4 . The supernatant obtained (0.5 ml) was mixed with 2 ml of 0.3 M disodium hydrogen phosphate. Then 0.25 ml of 0.001 M freshly prepared DTNB dissolved in 1% w/v sodium citrate was added and absorbance would be noted spectrophotometrically at 412 nm. Different concentrations of reduced glutathione (GSH) standard were processed similarly to prepare a standard curve (10-100 μ m). Results were expressed as micromoles of reduced glutathione per mg of protein.

PREPARATION OF REAGENTS**Preparation of 5, 5'-Dithiobis 2-Nitrobenzoic Acid (DTNB) Solution**

7.92 mg of DTNB was dissolve in 20 ml of 1% of sodium citrate.

Preparation of 1% of Sodium Citrate solution

1g of sodium citrate was dissolve in 100 ml of water.

Preparation of 0.3 M Disodium Hydrogen Phosphate (8.4pH)

4.26 g of anhydrous disodium hydrogen phosphate was dissolve in 100 ml distilled water.

Preparation of 10% Trichloroacetic Acid Solution

10 g trichloroacetic acid was dissolved in 100 ml distilled water.

Preparation of 100 μ M reduced glutathione

6.14 mg of reduced glutathione was dissolved in 200 ml distilled water

Estimation of Total Protein Content

Brain total protein was estimated by the method of Lowry *et al.* (1951) with slight modifications using bovine serum albumin (BSA) as a standard. 0.15 ml of supernatant tissue homogenate was diluted to 1 ml with distilled water and 5 ml of Lowry reagent was added. The contents were mixed thoroughly and the mixture was kept for 15 min at room temperature (37°C). Then, 0.5 ml of 1:1 v/v diluted Folin-Ciocalteu's reagent was added. The content was then be vortexed vigorously and incubated at room temperature (37°C) for 30 min. The protein content was determined spectrophotometrically at 750 nm against suitably prepared blank and a standard curve using 0.2-2.4 mg/ml of BSA was

plotted. The amount of total protein was expressed in mg/ml. The absorbance from a standard curve generated using 1,1,3,3 tetra-methoxy propane as standard (range = 1nmol -10 nmol) was extrapolated. The values was expressed as nmol per gm tissue.

PREPARATION OF REAGENTS

Preparation of Lowry Reagent:

Lowry reagent was prepared by mixing 1% w/v of copper sulphate, 2% w/v sodium potassium tartrate, 2% w/v of sodium carbonate in 0.1 M sodium hydroxide in a ratio of 1:1:98.

Preparation of 1% w/v of Copper Sulphate Solution

1g cupric sulphate was dissolved in 100ml distilled water.

Preparation of 2% w/v Sodium Potassium Tartrate Solution

2g of sodium potassium tartrate was dissolved in 100ml distilled water.

Preparation of 2% w/v of Sodium Carbonate Solution (Na₂ CO₃)

2g sodium carbonate was dissolved in 100ml distilled water.

Preparation of 0.1 M Sodium Hydroxide Solution

4g of NaOH was dissolved in 1000 ml distilled water.

Preparation of 2.4 mg/ml Bovine Serum Albumin (BSA) Solution

24 mg of BSA was dissolved in 10 ml distilled water.

Preparation of Folin-Ciocalteu's phenol Reagent Solution

Folin-ciocalteu's phenol reagent was prepared by diluting the equal volume of folin-ciocalteu's phenol reagent with distilled water in the ratio of 1:1.

Estimation of Brain Nitrite / Nitrate Concentration Level

The accumulation of nitrite in the supernatant was measured as an indicator of the production of nitric oxide determined by the method of Green *et al.* (1982) using a colorimetric assay with the Griess reagent (0.1% N-(1-naphthyl) ethylenediaminedihydrochloride, 1% sulphanilamide and mixture was incubated for 10 min at room temperature in the dark, and the absorbance was measured at 540 nm using a (UV-1800 spectrophotometer, shimadzu). The standard curve of sodium nitrite (5 to 50µM) was plotted to calculate concentration of brain nitrite.

Preparation of Reagents

Griess reagent was prepared by dissolving 1:1 solution of 1.0% of sulphanilamide in 5 M HCL solution and 0.1% N-naphthyl-ethylene-diamine in water.

Preparation of 1.0% Sulphanilamide Solution

1g of sulphanilamide was dissolved in 5 M HCL and volume was made upto 100 ml.

Preparation of 0.1 N- Nathy Lethylenediamine Solution

100 mg N- nathylethylenediamine was dissolved in 100 ml of distilled water.

Preparation of 5M HCL Solution

44.65 ml of concentration HCL was in 100 ml of distilled water.

Estimation of Brain Acetyl Cholinesterase (AChE) Activity

The cholinergic neuron marker acetyl-cholinesterase, will be estimated in whole brain according to the method of Ellman *et al.* (1961) with slight modifications (Koladiya *et al.*, 2009). It is measured on the basis of the formation of yellow color due to the reaction of thiocholine with dithiobisnitrobenzoate. The rate of formation of thiocholine from acetylthiocholine iodide in the presence of brain cholinesterase was measured using a spectrophotometer. 0.5 ml of supernatant of the brain homogenate was pipette out into a 25 ml volumetric flask and diluted with freshly prepared DTNB solution (10 mg DTNB in 100 ml of Sorenson phosphate buffer, pH 8.0). From volumetric flask, two 4 ml portions will be pipette out into two test tubes. Into one of the test tubes, two drops of eserine solution to be added. Then 1 ml of substrate solution (75 mg acetylcholine iodide per 50 ml of distilled water) will be pipette out into both of the test tubes. The test tube containing eserine was taken as blank and the change in absorbance per minute of the test sample was read using a spectrophotometer at 412 nm (Abhinav *et al.*, 2010; Kumar *et al.*, 2009). AChE activity was calculated using the following formula:

$$R = \frac{\delta O.D. \times \text{volume of assay}}{E \times \text{mg of protein}}$$

Where;

R = rate of enzyme activity in 'n' mole of acetylcholine iodide hydrolyzed/min/mg protein,

δ O.D. = change in absorbance/min,

E = Extinction coefficient (13600/M/cm)

PREPARATION OF REAGENTS

Preparation of 5,5'-Dithiobis (2-nitrobenzoic acid) DTNB

10 mg of DTNB was dissolved in 100 ml of Sorensen phosphate buffer

Preparation of Sorensen Phosphate Buffer (PH 7.4)

Sorensen phosphate buffer was freshly prepared by mixing 47.35 ml of 0.2 M dibasic sodium phosphate and 2.65 ml of 0.2 M monobasic sodium phosphate.

Preparation of 0.2 M Dibasic Sodium Phosphate Solution

0.2 M dibasic sodium phosphate was prepared by dissolving 35.6 g of dibasic sodium phosphate in distilled water and volume was made upto 1 litre with distilled water.

Preparation of 0.2 M Monobasic Sodium Phosphate Solution

0.2 M monobasic sodium phosphate was prepared by dissolving 27.6 g of monobasic sodium phosphate in

distilled water and volume was made upto 1 litre with distilled water.

Preparation of Acetylthiocholine Iodide Solution

75 mg of acetylthiocholine iodide was dissolved in 50 ml of distilled water.

Myeloperoxidase Activity

The myeloperoxidase (MPO) activity which is measured as an index of neutrophil accumulation which can be measured by using method of Krawisz *et al.*, (1984). In the pellet obtained after tissue homogenization 10 mL of ice-cold potassium phosphate buffer (pH 6.0) containing 0.5% hexadecyltrimethyl ammonium bromide (HETAB) and 10 mM ethylene diamine tetra acetic acid (EDTA) will be added and subjected to one cycle of freezing and thawing and then sonication for has been taken for 15 s. The contents will be centrifuged at 15,000 g for 20 minutes. 0.1 mL of supernatant obtained after centrifugation and mixed with 2.9 mL of phosphate buffer containing 0.16 mg/mL of o-dianisidine hydrochloride and 0.0005% hydrogen peroxide (H₂O₂). The change in absorbance was measured by using spectrophotometer at 460 nm. The MPO activity is expressed as unit per gram of tissue weight where 1 unit is the quantity of enzyme able to convert 1 μ M of H₂O₂ to water in 1 minute at room temperature. The calculation of MPO activity will be done using formula:

$$\text{MPO activity (U/g)} = X / \text{Weight of the tissue}$$

Where X = 10 x change in absorbance per minute/volume of supernatant taken in mL

Histological Evaluation

Haematoxylin and eosin staining of brain tissue will be done for histological parameters. The brain tissues will be preserved in 10% formalin and dehydrated in graded concentrations of ethanol, immersed in xylene and then embedded in paraffin. The sections of 4 μ m thickness will be cut and placed on slide using commercial Baker's mounting fluid. Paraffin wax will be removed by warming the slide gently, until the wax melts and then will be washed with xylene. This was followed by washings with absolute alcohol and water to hydrate the sections and stained with haematoxylin and eosin described by Clayden (1971). The hydrated sections were stained with haematoxylin for 15 min. The stained sections will be washed with water and they will be treated with 1% acid alcohol mixture for 20s. The acid alcohol mixture washed off with water and sections will be counterstained with 1% aqueous solution of eosin for 2 minutes. After washing with water to remove excess of eosin, the sections was dehydrated using absolute alcohol and then mounted using Canada balsam as mounting agent. The slides were observed for gross histopathological changes and neutrophil accumulation.

Treatment Schedule

All animals were acclimatized for atleast 2 hrs before testing unless otherwise specified in all the experiments. Animals were divided in seven groups and each group consisted of six animals as approved by IAEC for the post emptive paradigms. To evaluate the effect of Ascorbic Acid (100, 200 mg/kg, *i.p*) treatment was initiated on the 1st day and continued till 14th day and 3-nitropropionic acid was also administered along with Ascorbic Acid.

EXPERIMENTAL PROTOCOL

Group I (Control, n= 6)

Rats were administered with normal saline (10 mg/kg/day, i.p) 30 min before the acquisition trails conducted from day 1 to day 4 and 30 min before retrieval trail conducted on day 5 using Morris water maze (MWM) test.

Group II (DMSO Control, n= 6)

Rats were administered with DMSO (1mg/kg/day, i.p) daily for 14 days followed by exposure to MWM test.

Group III (Olive Oil Control, n=6)

Rats were administered with Olive Oil (1mg/kg/day, i.p) daily for 14 days followed by exposure to MWM test.

Group IV (3- NP Control, n= 6)

The rats were administered with 3- Nitro-proponic acid (3- NP) dose (10 mg/kg/day, i.p, 0.9 % w/v, i.p) for 14 days followed by the exposure to the MWM test.

Group V (Ascorbic Acid per se, n= 6)

Rats were administered with ascorbic acid (200 mg/kg/day, i.p), 30 mins before acquisition trails from day 1 to day 4

Group VI (3-NP + Ascorbic acid (LD), n=6)

Ascorbic acid (100 mg/kg/day, i.p) was administered to rats 30 mins before 3-NP (10 mg/kg/day, i.p) administration.

Group VII (3- NP + Ascorbic acid (HD), n=6)

Ascorbic acid (200 mg/kg/day, i.p) was administered to rats 30 mins before 3- NP (10 mg/kg/day, i.p) administration.

Group VIII (Bicuculline + Ascorbic acid (HD) + 3NP, n=6)

Bicuculline (10 mg/kg/day,i.p) was administered to rats 30 mins before Ascorbic acid. Ascorbic acid (200 mg/kg/day,i.p) was administered 30 mins before 3-NP.

Group IX (Mifepristone + Ascorbic acid (HD) + 3-NP. N=6)

Mifepristone (1mg/kg/day, i.p) was administered to rats 30 mins before Ascorbic acid. Ascorbic acid (200mg/kg/day, i.p) was administered 30 mins before 3-NP (10mg/kg/day, i.p).

RESULTS

Effect of Ascorbic Acid on Body Weight of Animals

There was no change in the initial and final body weight of control animals. However, 3-NP treatment caused a significant decrease in body weight on day 15th as compared to control group. Ascorbic Acid *per se* (200 mg/kg, i.p) and vehicle treatment had no effect on body weight, however pre-treatment with Ascorbic Acid (100 mg/kg and 200 mg/kg, i.p) on 3-NP treated rats significantly and dose dependently prevented the decrease in the body weight (Table 1). Moreover

treatment with Bicuculline (1 mg/kg, *i.p*) and Mifepristone (1mg/kg/day, *i.p*) significantly abolished the effects of Ascorbic acid.

Effect of Ascorbic Acid on Memory and Learning using Morris Water Maze

All the animals showed an initial increase in escape latency, which declined with continued training during the acquisition of a spatial navigation task. The mean retention latencies to escape onto the hidden platform did not alter in control rats on all days throughout the experiment. However, the mean retention latencies in the 3-NP (10 mg/kg, *i.p*) treated rats were increased significantly ($p < 0.05$) after initial training in the water maze on days 5th and 15th of 3-NP as compared to control group. The time spent in the target quadrant (TSTQ) was also decreased in the 3-NP treated rats as compared to control group. Ascorbic acid (200 mg/kg *i.p.*) *per se* and vehicle treatment had no effect on memory and learning when compared with control group. Moreover, treatment with bicuculline (1 mg/kg, *i.p*) abolished and Mifepristone (1mg/kg/day, *i.p*) the ascorbic acid mediated reduction in retention latencies (Figure 1).

Effect of Ascorbic Acid on Elevated Plus Maze Activity

In this study, the mean initial transfer latencies (ITL) on day 1 before 3-NP treatment for each rat was relatively stable and showed no significant variation. All the rats entered the closed arm within 96 sec. The vehicle and control treated rats entered the closed arm quickly, and the mean retention transfer latencies (1st RTL and 2nd RTL) to enter the closed arm on days 5 and 15 were shorter as compared to the ITL on day 1 of each group. In contrast, the 3-NP (10 mg/kg, *i.p*) treated rats performed poorly throughout the experiment and an increase in the mean retention transfer latencies on day 5 and 15 was noted as compared to the pre-training latency on day 1, demonstrating 3-NP induced cognitive dysfunction. Ascorbic Acid administration (100 mg/kg and 200 mg/kg, *i.p*) to 3-NP (10 mg/kg, *i.p*) treated rats significantly decreased the mean retention latencies on day 5 and day 15 indicating an improvement in memory impairment induced by 3-NP. However, ascorbic acid (200 mg/kg *i.p.*) *per se* treatment had no effect on memory when compared with control group. Moreover, treatment with bicuculline (1 mg/kg, *i.p*) and Mifepristone (1mg/kg/day, *i.p*) abolished the effect of ascorbic acid (Figure 2).

Effect of Ascorbic Acid on Grip Strength Using Rotarod Activity

3-NP (10 mg/kg, *i.p*) treatment impaired grip strength as assessed by rotarod test on 5th day and 15th day. Pre-treatment with ascorbic acid (100 mg/kg and 200 mg/kg, *i.p*) significantly ($P < 0.05$) attenuated the 3-NP induced decrease in grip strength in a dose dependent manner on day 5 and 15. However, ascorbic acid *per se* (200 mg/kg, *i.p*) and vehicle treatment had no effect on grip strength activity when compared with control group. Moreover, treatment with Bicuculline (1 mg/kg, *i.p*) and Mifepristone (1mg/kg/day, *i.p*) significantly abolished the Ascorbic acid mediated increase in grip strength (figure 3).

Effects of Ascorbic Acid on Gross Locomotor Activity Using Actophotometer

3-NP administration caused significant decrease in the locomotor activity on day 5 and day 15 as compared to control group. Pre-treatment with ascorbic acid (100 mg/kg and 200 mg/kg, *i.p*) significantly ($P < 0.05$) attenuated the 3-NP (10 mg/kg, *i.p*) induced decrease in motor activity in a dose dependent manner on day 5 and day 15 and there was no change in the locomotor activity of vehicle treated rats as compared to control group. However, ascorbic acid *per se* (200 mg/kg, *i.p.*) and vehicle treatment had no effect on gross behavioral activity when compared with control group. Moreover,

treatment with bicuculline (1 mg/kg, *i.p*) and Mifepristone (1mg/kg/day, *i.p*) significantly abolished the ascorbic acid mediated increase in motor activity (figure 4).

Effects of Ascorbic Acid on Brain Reduced Glutathione Levels

GSH levels in 3-NP (10 mg/kg, *i.p*) administered rats have shown significant ($P<0.05$) decrease as compared with control group whereas, there was no effect of ascorbic acid (200 mg/kg, *i.p*) *per se* and vehicle treatment on brain GSH levels. Pre-treatment with ascorbic acid (100 mg/kg and 200 mg/kg, *i.p*) significantly ($P<0.05$) attenuated 3-NP induced decrease in GSH levels. Moreover, treatment with bicuculline (1 mg/kg, *i.p*) and Mifepristone (1mg/kg/day, *i.p*) abolished the ascorbic acid mediated increase in brain GSH levels (Figure 5).

Effect of Ascorbic Acid on Brain Lipid Peroxidation Level

Systemic administration of 3-NP (10 mg/kg, *i.p*) caused a marked increase in lipid peroxidation in addition to a decline in antioxidant defense, as indicated by a significant ($P<0.05$) rise in brain MDA levels as compared to the control rats. Further, there were no alterations in the brain MDA level due to ascorbic acid (200 mg/kg, *i.p*) *per se* and vehicle treatment as compared to control group. Pretreatment with ascorbic acid (100 mg/kg and 200 mg/kg, *i.p*) significantly ($P<0.05$) prevented the increase in MDA levels, with marked effect observed at the highest dose when compared to the 3-NP treated group. Moreover, treatment with bicuculline (1 mg/kg, *i.p*) and Mifepristone (1mg/kg/day, *i.p*) abolished the protective effects of ascorbic acid (Figure 6).

Effect of Ascorbic Acid on Brain Nitrite Levels in 3-Nitropropionic Acid Treated Rats

In present study, there was no significant effect of ascorbic acid *per se* (200 mg/kg, *i.p*) and vehicle treatment on brain nitrite levels as compared to control rats. Systemic 3-NP (10 mg/kg, *i.p*) administration caused a significant ($P<0.05$) increase in brain nitrite levels, which was significantly ($P<0.05$) prevented by pretreatment with ascorbic acid (100 mg/kg and 200 mg/kg, *i.p*) in a dose dependent manner. Moreover, treatment with bicuculline (1mg/kg, *i.p*) and Mifepristone (1mg/kg/day, *i.p*) abolished the ascorbic acid mediated reduction in brain nitrite levels (Figure 7).

Effect of Ascorbic Acid on Acetylcholinesterase Levels

3-NP (10 mg/kg, *i.p*) administration caused significant ($P<0.05$) increase in acetylcholinesterase enzyme levels of test animals when compared to control group. Ascorbic acid treatment significantly ($P<0.05$) attenuated acetylcholinesterase enzyme activity as compared to 3-NP treated rats. Moreover, there was no significant effect of ascorbic acid (200mg/kg, *i.p*) *per se* and vehicle treatment on brain acetylcholinesterase levels as compared to control group. Furthermore, treatment with bicuculline (1mg/kg, *i.p*) and Mifepristone (1mg/kg/day, *i.p*) abolished the ascorbic acid mediated reduction in acetylcholinestrerase enzyme levels (Figure 8).

Effect of Ascorbic Acid on Brain Myeloperoxidase (MPO) Activity

Systemic administration of 3-NP (10 mg/kg, *i.p*) caused a marked increase in MPO activity as compared to the control group. Further, there were no alterations in the brain MPO activity due to ascorbic acid (200 mg/kg, *i.p*) *per se* and vehicle treatment as compared to control rats. Ascorbic acid (100 mg/kg and 200mg/kg, *i.p*) administration for 14 days, however, significantly ($P<0.05$) prevented the increase in MPO activity, with marked effect observed at the highest dose when compared to 3-NP treated group. Moreover, treatment with bicuculline (1 mg/kg, *i.p*) and Mifepristone (1mg/kg/day,

i.p) abolished the ascorbic acid mediated reduction in brain MPO activity (Figure 9).

Table 1: Effects of Various Interventions on Body Weight of Animals

Group. No	Treatment	Initial Body weight(g)	Final Body weight(g)
1	Control	222.5±6.5	219±7.4
2	DMSO	220.6±9.2	218.3±8.3
3	Olive Oil	220.4±7.6	219.5±4.6
4	3-NP	221.6±8.8 ^a	208.0±8.4
5	Ascorbic acid	220.0±10.4	218.3±6.5
6	LD + 3-NP	220.6±9.7 ^b	213.6±7.3
7	HD + 3-NP	220.0±7.7 ^b	217.3±7.6
8	Bicuc + Ascorbic acid(HD) + 3-NP	221.6±8.5 ^c	210.3±6.0
9	Mife + Ascorbic acid (HD) + 3-NP	220.5±8.6 ^c	218.5±6.7

Values are the Mean ± S.E.M

a= p<0.05 as compared to the normal control

b= p< 0.05 as compared to the 3-NP injected group

c= p< 0.05 as compared to HD+ 3-NP group.

D=p<0.05 as compared to Bicuc+ Ascorbic acid (HD) +3-NP




Figure 1: Effects of Ascorbic Acid on Memory and Learning Using Morris Water Maze (MWM) Test

Values are the mean ± SEM.

a= p<0.05 as compared to the normal control

b= p< 0.05 as compared to the 3-NP injected group

c= p< 0.05 as compared to HD+ 3-NP group.




Figure 2: Effects of Ascorbic Acid on Memory Performance in Elevated plus Maze Test

Values are the mean \pm SEM

a= $p < 0.05$ as compared to the normal control

b= $p <$ as compared to the 3NP injected group

c= $p < 0.05$ as compared to HD+ 3-NP group.




Figure 3: Effects of Ascorbic Acid on Grip Strength Using Rota Rod Test

Values are the mean \pm SEM

a= $p < 0.05$ as compared to the normal control

b= $p < 0.05$ as compared to the 3-NP injected group

c= $p < 0.05$ as compared to HD+ 3-NP group.




Figure 4: Effects of Ascorbic Acid on Locomotor Activity Using Actophotometer

Values are the mean \pm SEM.

a= $p < 0.05$ as compared to the normal control

b= $p < 0.05$ as compared to the 3-NP injected group

c= $p < 0.05$ as compared to HD+ 3-NP group.




Figure 5: Effects of Ascorbic Acid on Reduced Glutathione Levels

Values are the mean \pm SEM

a= $p < 0.05$ as compared to the normal control

b= $p < 0.05$ as compared to 3-NP injected group

c= $p < 0.05$ as compared to HD+ 3-NP group.




Figure 6: Effects of Ascorbic Acid on Lipid Peroxidation

Values are the mean \pm SEM

a= $p < 0.05$ as compared to the normal control

b= $p < 0.05$ as compared to 3-NP injected group

c= $p < 0.05$ as compared to HD+ 3-NP group.




Figure 7: Effects of Ascorbic Acid on Brain Nitrite/ Nitrate Levels

Values are the mean \pm SEM

a= $p < 0.05$ as compared to the normal control

b= $p < 0.05$ as compared to 3-NP injected group

c= $p < 0.05$ as compared to HD+ 3-NP group.




Figure 8: Effects of Ascorbic Acid on Brain Acetylcholinesterase (AChE) Activity

Values are the mean ± SEM

a= p< 0.05 as compared to the normal control

b= p< 0.05 as compared to 3-NP injected group

c= p< 0.05 as compared to HD+ 3-NP group.




Figure 9: Effects of Ascorbic Acid on Myeloperoxidase (MPO) Activity

Values are the mean ± SEM

a= p< 0.05 as compared to the normal control

b= p<0.05 as compared to 3-NP injected group

c= p< 0.05 as compared to HD+ 3-NP group

CONCLUSIONS

The present study was designed to evaluate the neuroprotective effects of Ascorbic Acid against 3-NP induced Huntington's disease in rats and possible involvement of GABA_A receptors.

On the basis of results obtained in the present study, the following salient findings are summarized:

- Control group animals had shown a good performance on MWM test and EMP test as reflected by normal memory and learning. In addition, they have shown normal motor activity in rota rod test and in actophotometer.
- Administration of ascorbic acid (200 mg/kg, *i.p.*) *per se* had no effect on acquisition, memory, motor activity and various biochemical parameters as compared to control group animals.
- Systemic administration of 3-NP (10 mg/kg, *i.p.* for 14 days) produced symptoms similar to Huntington's disease in rats such as declined motor function, poor retention of memory, exaggerated oxidative stress (↓GSH, ↑MDA & ↑iNOS), ↑AChE levels and ↑MPO activity along with neuro-degeneration.
- Pre-treatment with Ascorbic Acid (100 mg/kg and 200 mg/kg, *i.p.*) once daily for a period of 14 days attenuated 3-NP induced motor and cognitive impairment together with improvement in biochemical parameters (↑GSH, ↓MDA, ↓AChE, ↓MPO & ↓iNOS) in a dose dependent manner in rats.
- Pre-treatment with Bicuculline (1 mg/g, *i.p.*) once daily for a period of 14 days abolished the neuroprotective effects of ascorbic acid on 3-NP treated rats. In addition, histopathological changes in present study have further justified the approach.

In conclusion, the results of the present study demonstrate that ascorbic acid has shown neuroprotective effects against 3-NP induced behavioral and biochemical alterations similar to Huntington's disease in rats and the said role of ascorbic acid involves the activation of GABA-A receptors.

REFERENCES

1. A contribution to the history of Huntington's chorea: a preliminary report. *Neurographs* (1908).1116-1624
2. A randomized controlled trial (2006), *Neurology*. 66: 366-372
3. Aiken CT, Tobin AJ, Schweitzer ES (2004) A cell-based screen for drugs to treat Huntington's disease. *Neurobiol Dis*; 16: 546-555.
4. Albin RL, Reiner A, Anderson KD, Penney JB, Young AB (1990) Striatal and nigral neuron subpopulation in rigid Huntington's disease: Implications for the functional anatomy of chorea and rigidity-akinesia. *Ann Neurol*; 27:357-365.
5. Albin RL, Young AB, Penny JB (1989) the functional anatomy of basal ganglia disorders. *Trends Neurosci*;12:366-375.
6. Alexi T, Hughes PE, Faull RL, Williams CE (1998) 3-Nitropropionic acid's lethal triplet, cooperative pathways of neurodegeneration. *Neuroreport*; 9:pp.57-R64.
7. Ali Farhan, Singh Kumar, RaniSapna, Ahirwer Vinita, Khan Shaista (2011) protective effect of vitamin C against

- lead acetate toxicity in blood glucose level of albino rats. *IJPT'S, Journal of pharmacology and toxicology*, vol 1:2, Pp. 1-9.
8. Alston TA, Mela L, Bright HJ (1997) 3-nitropropionate: the toxic substance of indigofera is a suicide inactivator of succinate dehydrogenase. *Pre. Natl Acad. Sci. USA*; 74: 3767-3773.
 9. Anderassen OA, Ferrante RJ, Hughes DB, Klivenyi P, Dedeoglu A, Ona VO, Friedlander RM, Beal MF (2000) Malonate and 3-nitropropionic acid neurotoxicity are reduced in transgenic mice expressing on caspase-1 dominant negative mutant. *J Neurochem*; 75: 847-852.
 10. Andrews PR, Johnston GAR (1979) GABA agonists and antagonists. *Biochem Pharmacol* 28: 2697-2702.
 11. Andrews PR, Johnston GAR (1979) GABA agonists and antagonists. *Biochem Pharmacol* 28: 2697-2702.
 12. Anne B, Young, Helon S, Pan, Brian J, Ciliax & John B, Peng (1984) GABA and Benzodiazepine receptors in basal ganglia function. *Neuroscience Letter*, 47 (36)-367.
 13. Atasayar S, Gürer-Orhan H, Orhan H, Gürel B, Girgin G, Özgüne ş H (2009) Preventive effect of aminoguanidine compared to vitamin and C on cisplatin-induced nephrotoxicity in rats. *Exp. Toxicol. Pathol.* 6:23-32.
 14. Ayala A, Venero JL, Cano J, Machado A (2007) Mitochondrial toxins and neurodegenerative diseases. *Front Biosci*; 12: 986-1007.
 15. Aziz NA, Anguelova GV, Marinus J, Lammers GJ, Roos RA (2010) sleep and circadian rhythm alteration comdate with depression and cognitive impairment in huntington's disease. *Parkinsonisa Relat Disord*; 16, pp: 345-350.
 16. Bano D, Agostini M, Melino G, Nicotera P (2011) Ageing, neuronal connectivity and brain disorders: an unsolved ripple effect. *Mol Neurobiol*; 43: 124-130.
 17. Bao J, Sharp AH, Waster MV (1996) Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin. *Proc Natl Acad Sci USA*; 93: 5037-5047.
 18. Bates G (2003) Huntingtin aggregation and toxicity in Huntington's disease. *Lancet*; 361, 1642- 4.
 19. Bates GP, Murphy KP (2002) Huntington's disease. In *Huntington's Disease Oxford University Press, Oxford, UK*, 387-426.
 20. Baudic S, Maison P, Dolbeau G (2006) Cognitive Impairment Related to Apathy in Early Huntington's disease. *Dement GeriatrCognDisord*; 21: 316-321
 21. Beal MF (1992) Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? *Ann Neurol*; 31: 119-130.
 22. Beal MF (1994) Neurochemistry and toxin models in Huntington's disease. *Curr. Opin. Neurol*; 7: 542-547.
 23. Beal MF (1998) mitochondrial dysfunction in neurodegenerative disease. *Biochem. Acto*; 1366: 211-223.
 24. Beal MF (2000) Energetic in the pathogenesis of neurodegenerative disease. *Trends in Neuroscience*; 23:298-304.

25. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB (1986) Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. *Nature*; 321: 168-171.
26. Biglan K, Shoulson I (2007) Juvenile onset Huntington's disease: A matter of perspective *Arch. Neuronal*; 64: 783-784.
27. Binfare RW, Rosa AO, Lobatok KR, Santos ARS, Rodrigues A (2009) Ascorbic acid administration produces an antidepressant like effect: evidence for the involvement of monoaminergic neurotransmission. *Progress in neuropsychopharmacology and Biological Psychiatry*; 33: 530-40.
28. Biolsi B, Cif L, Fertit HE, Robles SG, Coubes P (2008) Long-term follow-up of Huntington disease treated by bilateral deep brain stimulation of the internal globus pallidus. *J Neurosurg.* 109:130– 132.
29. Blum D, Wu Y, Nissou MF, Amaud S, Alim Louis B, Verma JM (1997) p53 and Bax activation in 6-hydroxydopamine-induced apoptosis in PC12 cells. *Brain Res*; 751(1): 139-142.
30. Bodner RA, Outeiro TF, Altmann S, Maxwell MM, Cho SH, Hyman BT (2006) Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. *ProcNatlAcadSciUSA* ; 103: 4246–4251.
31. Bonelli MR, Gregor KW, Kapfhammer PH (2004) Huntington's disease: present treatments and future therapeutic modalities. *International Clinical Psychopharmacology*; 19: 51-62.
32. Bonelli RM, Hofmann P (2004) A review of treatment options for Huntington's disease. *Expert Opin. Pharmacother*; 5: 767-776.
33. Bossy-Wetzell E, Schwarzenbacher R & Lipton SA (2004) Molecular pathways to neurodegeneration. *Nat Med*; 10 Suppl, S2-9.
34. Brouillet E, Conde F, Beal MF, Hantraye P (1999) Replicating Huntington's disease phenotype in experimental animals. *ProgNeurobiol*; 59: 427-68.
35. Brouillet E, Guyot MC, Mittoux V, Altairac, S, Conde F, Palfi S (1998) Partial inhibition of brain succinate dehydrogenase by 3- nitropropionic acid is sufficient to initiate striatal degeneration in rat. *J Neurochem*; 70: 794-805.
36. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muquit MM, Bird ED, Beal MF (1997) Oxidative damage and metabolic dysfunction in Huntington's disease. *Brain Pathol*; 9: 147-163.
37. Browne SE, Ferrante RJ, Beal MF (1990) Oxidative stress in the Huntington's disease. *Brain Pathol*;9:147-163.
38. Butterfield DA, Castegna A, Lauderback CM, Drake J (2002a) Evidence that amyloid beta-peptide –induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. *Neurobiol Aging*;23(5):655-664.
39. Butterfield DA, Griffin S, Much G, Pasinetti GM (2002b) Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. *J Alzheimers Dis*; 4(3):193-201.

40. Celada P, Paladini CA & Tepper JM (1999) GABAergic control of rat substantia nigra dopaminergic neurons, Role of globus pallidus and substantia nigra pars reticulata. *Neuroscience*, 89, 813±825.
41. Chen CM, Wu YR, Cheng ML, Liu JL, Lee YM, Lee PW, Soong BW, Chiu DT (2007) Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients. *Biochem. Biophys Res. Communun*; 359: 335-340.
42. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S (2000). Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. *Nat Med*; 6: 797-801
43. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP (2005) Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. *Proc Natl Acad Sci*. 102: 13604-13609.
44. Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC (2007) Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. *Proc Natl Acad*. 104: 8749-8754.
45. Chevalier G, Deniau JM (1990) Disinhibition as a basic process in the expression of striatal functions. *Trends Neurosci*. 13:277–280.
46. Chevalier G, Deniau JM (1990) Disinhibition as a basic process in the expression of striatal functions. *Trends Neurosci*. 13:277–280.
47. Ciavardelli D, Silvestri E, ViscovoAD, Bombam, Gregorio DD, Moreno M (2010) Alterations of brain and cerebellar proteomes linked to Abeta and tau pathology in a female triple- transgenic murine model of Alzheimer's disease. *Cell Death Dis*; 1: e90.
48. Coles CJ, Edmondson DE, Singer TP (1979) Inactivation of succinate dehydrogenase by 3- Nitropropionic, *J. Biol Chem*. 254, 5161-67.
49. Colle D, Santos DB, Moreira ELG, Harteig JM, Santos AAD, Zpmmermann LT, Hort MA, Farina M (2013) Probucal increases striatal glutathione peroxidase activity and protects against 3-NP induced pro-Oxidative damage in rats. *PLOS one* 8(6): e67658, pp 1-15.
50. Costa V, Giacomello M, Hudec R, Lopreiato R, Ermak G, Lim D (2010) Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli. *EMBO Mol Med*; 2: 490–503.
51. Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate, and neurodegenerative disorders. *Science*. 262:689–695.
52. Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate, and neurodegenerative disorders. *Science*. 262:689–695.
53. Cummings JL (1995) Behavioral and psychiatric symptoms associated with Huntington's disease. *AdvNeurol*; 65:179-186.

54. Daniel T, Organiscia K, Yih-ling, HinminWang & INA Bicknell (1990) The protective effect of ascorbic acid in retinal light damage of rats exposed to intermittent light. *Invest Ophthalmol Vis Sci*, 31: 1195-1202.
55. Datta Abhishek, Zhou Xiang, Su Yuzhou, Parra LC & Bikson Marom (2013) Validation of finite element model of transcranial electrical stimulation using scalp potentials: implications for clinical dose. *J. Neural Eng.* 10; 036018 (10pp).
56. Davis JD, Filoteo JV, Maddox WT (2001) A possible role of the striatum in linear and nonlinear category learning: evidence from patients with Huntington's disease. *BehavNeurosci*; 123: 234-239.
57. Deckel AW, Gordinier A, Nuttal D, Tang V, Kuwada C, Freitas R. And Gary KA (2001) Reduced activity and protein expression of NOS in r6/2 HD transgenic mice. Effects of L-NAME on symptom progression. *Brain Res*; 919(1): 70-81.
58. DeLong MR (1990) Primate models of movement disorder of basal ganglia origin, *TINS*, 13:281-285.
59. DelvalA, Krystkowiak P, Blatt JL (2006) Role of hypokinesia and bradykinesia in gait disturbances in Huntington's disease- A biomechanical study. *J Neurol*;253:73-80.
60. DiFiglia, M (1995) Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. *Neuron*; 14: 1075-81.
61. Douglas PM, Dillin A (2010) Protein homeostasis and aging in neurodegeneration. *J Cell Biol*; 190: 719-729.
62. Dragunow M (1995) In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. *Neuroreport*; 6: 1053-7.
63. Edwards NL (2008) The role of hyperuricemia and gout in kidney and cardiovascular disease. *Cleve. Clin. J. Med.* 75:S13-S16.
64. Eichenbaum H (2004) Hippocampus: cognitive processes and neural representations that underlie declarative memory. *Neuron*. 44:109-120.
65. Emerich DF, Thanos CG, Goddard M, Skinner SJ, Geany MS, Bell WJ, Bintz B, Schneider P, Chu Y, Babu RS, Borlongan CV, Boekelheide K, Hall S, Bryant B, Kordower JH (2006) Extensive neuroprotection by choroid plexus transplants in excitotoxinlesioned monkey. *NeurobiolDis*; 23: 471-480.
66. Fasano A, Mazzone P, Piano C, Quaranta D, Soleti F, Bentivoglio AR (2008) GPi-DBS in Huntington's disease: results on motor function and cognition in a 72-year-old case. *MovDisord.* 23:1289-1292.
67. Fasano A, Mazzone P, Piano C, Quaranta D, Soleti F, Bentivoglio AR (2008) GPi-DBS in Huntington's disease: results on motor function and cognition in a 72-year-old case. *Mov Disord.* 23:1289-1292.
68. Faull RLM, Waldvogel HJ, Nicholson LFB, Synek BJJ (1993) The distribution of GABA A- benzodiazepine receptors in the basal ganglia in Huntington's disease and in quinolinic acid lesioned rats. *Prog Brain Res*; 99: 105-123.
69. Ferdinandy P, Schulz R (2003) Nitric oxide superoxide and peroxynitrite in myocardial ischaemia reperfusion injury and preconditioning. *Br. J. Pharmacol*; 138: 532-543.

70. Fleury C, Mignotte B and Vayssiere JL (2002) Mitochondrial reactive oxygen species in cell death signaling. *Biochimie*; 84(2-3): 131-141.
71. Folstein MF, Folstein SE, Jensen B, Leigh RJ (1983) The measurement of abnormal movement: methods developed for Huntington's disease. *Neurobehav Toxicol Teratol*; 5: 605-609.
72. Friedlander R (2003) Apoptosis and caspases in neurodegenerative diseases. *N Engl J Med*; 348: 1365-75
73. Fritschy JM, Kiener T, Bouillerd V, Loup F (1999) GABAergic lobe epilepsy. *Neurochem Intermat*; 34: 435-445.
74. Furtado JC, Mazurek MF (1996) Behavioral characterization of quinolinate-induced lesions of the medial striatum: Relevance for Huntington's disease. *Exp Neurol*; 138:158-168
75. Gao X, Curhan G, Forman JP, Ascherio A, Choi HK (2008) Vitamin C intake and serum uric acid concentration in men. *J. Rheumatol.* 35:1853-1858.
76. Gardian G and Vecsei L (2004) Huntington's disease: patho- mechanism and therapeutic perspectives. *J. Neural Transm*; 111: 1485–1494.
77. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. *Cell* ; 140: 918–934.
78. Glass L, Dragunow M, Faull RLM (2000) The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA A receptors alterations in the human basal ganglia in Huntington's disease. *Neuroscience*; 97: 505-519.
79. Goldberg Y (1997) Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. *Nat Genet*; 13: 442-9.
80. Goodman M, Bostick RM, Kucuk O, Jones DP (2011) Clinical trials of antioxidant as cancer prevention agents: past, present and future. *Free radic Biol Med* ; 51: 1068-1084.
81. Goswami A, Dikshit P, Mishra A, Mulherkar S, Nukina N, Jana NR (2006) Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction. *Biochem. Biophys. Res. Commun*; 342: 184-190.
82. Gould DH, Wilson MP and Harmar DW (1985) Brain enzyme and clinical alterations induced in rats and mice by nitro aliphatic toxicants. *Toxicol. Lett*; 27: 83-89.
83. Graham AR Johnston (2013) Advantages of an antagonist: bicuculline and other GABA antagonists *British Journal of Pharmacology*, page no: 328-336.
84. Graybiel AM (1990) Neurotransmitters and neuromodulators in the basal ganglia. *Trends in Neuroscience* ; 13: 244-254.
85. Graybiel AM and Ragsdale Jr. CW (1983) *Biochemical anatomy of the striatum. Chemical Neuroanatomy*, Raven Press, New York, pp. 427-504.
86. Grünewald RA (1993) Ascorbic acid in the brain. *Brain Res. Rev.* 18, 123–133

87. Grünewald RA, (1993) Ascorbic acid in the brain. *Brain Res. Rev.* 18, 123–133
88. Grünewald T, Beal MF (1999) Bioenergetics in Huntington's disease. *Ann N Y AcadSci*; 893: 203-213.
89. Gutekunst AC, Francine N, Hersch MS (2000) Recent advances in Huntington's disease. *Current Opinion in Neurology*; 13: 445-450.
90. Gutekunst CA, Norflus F, Hersch SM (2002) The neuropathology of Huntington's disease. In *Huntington's Disease* (eds. Bates, G.P., Harper, P.S. & Jones, A.L.), Oxford University Press, Oxford, UK, 251-75.
91. Guyot MC, Hantraye P, Dolan R, Palfi S, Maziere M, Brouillet E (1997) Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. *Neuroscience*; 79: 45-56.
92. Hackam AS (1998) The influence of huntingtin protein size on nuclear localization and cellular toxicity. *J Cell Biol*; 141: 1097-105.
93. Halliwell B (2006) Oxidative stress and neurodegeneration. Where are we now? *J. Neurochem*; 97: 1634-1658.
94. Harjes P, Wanker EE (2003) The hunt for huntingtin function: interaction partners tell many different stories. *Trends BiochemSci*; 28: 425-33.
95. Harper PS (1986) The epidemiology of Huntington's disease. *Hum Genet*; 89: 365-376.
96. Harrison FE, May JM (2009) Vitamin C function in the brain: vital role of the ascorbate transporter SVCT2. *Free RadicBiol Med*; 46(6):719-30.
97. Hart EP, Marinus J, Burgunder JM (2013) for the registry investigators of the European huntington's disease network. Better global and cognitive functioning for choreatic versus hypokinetic rigid huntington's disease. *Mov Disord.* 28; pp:1142-1145.
98. Hassel B, Sonnewald U (1995) Selective inhibition of the tricarboxylic acid cycle of GABAergic neurons with 3-nitropropionic acid in vivo. *J Neurochem*; 65: 1184-1191.
99. Heidari N, Hicks MA, Harada H (2010) GX15-070 (obatoclox) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. *Cell Death Dis*; 1: e76.
100. Henley SM, Wild EJ, Hobbs NZ, Frost C, Mac Manus DG, Barber RA, Fox NC, Tabrizi SJ (2009) Whole brain atrophy as a measure of progression in premanifest and early Huntington's disease. *MovDisord*; 24: 92-96.
101. Hickey M, Chesselet M (2003) Apoptosis in Huntington's disease. *Prog Neuropsychopharmacol Biol Psychiatry* ; 27: 255-65.
102. Ho LW (2001) The molecular biology of Huntington's disease. *Psychol Med*; 31: 3-14.
103. Hodgson JG, Agopyam N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ (1999) A YAC mouse model for huntington's disease with full length mutant huntingtin, cytoplasmic toxicity and selective striatal neurodegeneration. *Neuron*; 23: 181-192.
104. Huntington's disease. *Seminar in Neurology* (1999); 19: 385-395.

105. Idetel, Ferrira, Marria, Nascimento, Marcis Ribeiro, Sandra Alneide, Sandra M. Cerdaso, Manuela Garina (2010) mitochondrial dependent apoptosis in Huntington's disease human cybrids, *Experimental Neurology* XXX. No. of pages 13.
106. Idogun ES & Ajala MO (2005) Ascorbic Acid and Alpha Tocopherol Antioxidant Status of Type 2 Diabetes Mellitus Patients seen in Lagos. *The Nigerian Postgraduate Medical Journal*, 12 (3): 155-157.
107. Irene L. Llorente, Diego Perez-Rodriguez, Beatriz Martinez- Villayandre, Severiano Dos- Anjos, Mark G. Darlison, Amy V. Poole, Arsenio Fernandez-Loper (2013) GABA-A receptor chloride channels are involved in the neuroprotective role of GABA following oxygen and glucose deprivation in the rat cerebral cortex but not in the hippocampus. *Brain research*. 1533, 141-151.
108. Isacson O, Brundin P, Gage FH, Bjorklund A (1984) Functional neuronal replacement by grafted striatal neurons in the ibotenic acid lesioned rat striatum. *Nature* 311:458-460.
109. Jack DeRuiter (2004) *Principles of Drug Action 2*.
110. Jessica CJ, Bawden CV, Stuye RR, Clive JM, Suzanne JR, Henry JW, James FG, Simon KW, Russell GS, Mark IR, Richard LM (2010) An ovine transgenic Huntington's disease model. *Human molecular genetics*; 19(10): 1873-1882.
111. Jetti I, Raghuveer CV, Mallikarjuna RC, Somayaji SN, Prakash Babu B (2014) Neuroprotective effect of Ascorbic acid and Ginkgo biloba against Fluoride caused Neurotoxicity Raghu, *IOSR Journal Of Environmental Science, Toxicology And Food Technology (IOSR-JESTFT)*, Volume 8, Issue 1 Ver. V, PP 30-36.
112. Jha S, Patel R (2004) Some observations on the spectrum of dementia. *Neurol India*; 52:213-214.
113. John B, Penney JR, Anne B. Youy (1981) GABA on pallidothalamic neurotransmitter implications for basal ganglia function. *Brain Research*; 207: 195-199.
114. Johnston GAR (1991) GABAA antagonists. *Semin Neurosci* 3: 205-210.
115. Johnston GAR (2013) Advantages of an antagonist: bicuculline and other GABA antagonists *British Journal of Pharmacology*, page no: 328-336.
116. Johnston Graham AR (2005) *The Adrien Albert Laboratory of Medicinal Chemistry, Department of Pharmacology, Bentham Science Publishers Ltd.* 11, 1867-1885.
117. Jones L (2002) *The cell biology of Huntington's disease. In Huntington's Disease (eds. Bates, G.P., Harper, P.S. & Jones, A.L.), Oxford University Press, Oxford, UK, 349-86.*
118. Jones-Davis DM, Macdonald RL (2003) GABAA receptor function and pharmacology in epilepsy and status epilepticus. *Curr Opin Pharmacol*; 3: 12-18.
119. Jung ME, Shaw TJ (1980) *J. Am. Chem. Soc.* 102, 6304-6311.
120. Kara Y, Kumbul DD, Kulac E, Gultekin F (2014) Acetylsalicylic acid and via antioxidant effect or increased expression of NMDARs and nAChRs. *Environmental Toxicology and pharmacology*, 37: 916-927.

121. Kara Yusuf, Kumbul Duygu Doguc, Kulac Esin, Gultekin Faith (2014) Acetylsalicylic acid and via antioxidant effect or increased expression of NMDARs and nAchRs. *Environmental Toxicology and pharmacology*, 37: 916-927.
122. Karpuj MV, Becher MW, Springer JE (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease with administration of the transglutaminase inhibitor cystamine. *Nat Med*; 8:143-149.
123. Keller JN and Glazner GW (2000) Mitochondrial Oxidative stress and metabolic alterations in neurodegeneration disorders, *Interorganellar signaling in age related Disease*: 205-237.
124. Kendall AL, David F, Rayment G, Torres EM, Annett LE, Dummett SB (2000) The influence of excitotoxic basal ganglia lesions on motor performance in the common marmoset. *Brain* 123; (pt 7): 1442-1458.
125. Kent A (2004) Huntington's disease. *Nurs Stand*, 21, 45-51.
126. Kiani H, Hahi JH, Salehi A, Raissi V, Raissi O (2014) Combined treatment of ascorbic acid receptor agonist and ascorbic acid protects vulnerable neurons in mouse temoral cortex following ischemia reperfusion. *Global Journal of medicine researches and studies*, vol 2, pp.32-36.
127. Kiechle T (2002) Cytochrome C and caspase-9 expression in Huntington's disease. *Neuromolecular Med*; 1: 183-95.
128. Kleppner SR, Tobin AJ (2001) GABA signalling: therapeutic targets for epilepsy, Parkinson's disease and Huntington's disease. *Expert Opin Ther Targets*; 5:219-239.
129. Klivenyi P, Bende Z, Hartai Z (2006) Behaviour changes in a transgenic model of Huntington's disease. *Behav Brain Res*; 169:137-141.
130. Korkmaz A, Kolankaya D (2009). The protective effects of Ascorbic acid against renal ischemia rats. *Ren Fail*; 31:36.
131. Kulkarni SK (1999) *Handbook of experimental pharmacology*, VPBN 15, pp 1-209.
132. Kulkarni SK, Reddy DS (1998) Possible role of nitric oxide in the nootropic and anti-amnesic effects of neurosteroids on aging and dizocilipine induced learning impairment. *Brain Res*; 799:215-29.
133. Kumar P, Kalaria A (2010) Huntington's disease. *Pathogenesis to animal models*. *Pharmacol Rep*; 62: 1-14.
134. Kumar P, Kumar A (2008) Prolonged pretreatment with carvedilol prevents 3-nitropropionic acid induced behavioral alterations and oxidative stress in rats. *Pharmacol Reports*; 60: 706-715.
135. Kumar P, Kumar A (2009) Neuroprotective effect of cyclosporine and FK506 against 3 nitropropionic acid induced cognitive dysfunction and glutathione redox in rat: possible role of nitric oxide. *Neurosci Res*.; 63: 302-314.
136. Kumar P, Padi S.S.V, Naidu P. S, Kumar A (2006) *Annal of Neuroscience*., 13: 41-47.
137. Kumar P, Padi SS, Naidu PS, Kumar A (2007) cyclooxygenases inhibition attenuates 3-Nitropropionic acid

- induced neurotoxicity in rats: possible antioxidant mechanisms. *Fundam Clin Pharmacol*; 21: 297-306.
138. Kwang JQ, Beal MF, Manfredi G (2006) The role of mitochondrial in inherited neurodegeneration disease. *J. Neurochem.* 97: 1659-1675.
139. Lagowska-Lenard M, Stelmasiak Z, Bartosik-Psujek H (2010) Influence of vitamin C on markers of oxidative stress in the earliest period of ischemic stroke. *Pharmacol. Rep.* 62:751–756.
140. Landles C, Bates GP (2004) Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. *EMBO Rep*; 5: 958-63.
141. Leavitt BR (2001) Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. *Am J Hum Genet*; 68: 313-24.
142. Lemiere J, Decruyenaere M, Evers-Kieboomsh, Vandenbusche E, Dom R (2004) cognitive changes in patients with Huntington's disease and asymptomatic carriers of the HD mutation a longitudinal follow-up study. *J. Neurol*; 25: pp: 935-942.
143. Leonard B, Maes M (2012) Mechanistic explanations how cell mediated immune activation, inflammation and oxidative and their sequels and concomitants play a role in pathophysiology of unipolar depression. *Neuroscience and Biobehavior review*, vol 36 (2), pp 764-78.
144. Levine MS, Cepeda C, Hicky MA, Fleming SM, Chesselet MF (2004) Genetic mouse models of Huntington's disease and Parkinson's disease. *Illuminating but imperfect. Trends Neurosci*; 27: 691-697.
145. Li SH, Li XJ (2004) Huntingtin-protein interactions and the pathogenesis of Huntington's disease. *Trends Genet*; 20: 146-54.
146. Lin CH, Tallaksen –Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB, Ren S, Li XJ (2001) Albin – in mouse model of Huntington's disease. *Hum Mol Genet*; 10: 137-144.
147. Liu A, Honma I, Zhou H (2007) Simultaneous voltammetric detection of dopamine and uric acid at their physiological level in the presence of ascorbic acid using poly (acrylic acid)-multiwalled carbon-nanotube composite-covered glassy-carbon electrode. *Biosens Bioelectron.* 23:74–80.
148. Liu X, Zhang Y, Li J, Wang D, Wu Y, Li Y, Lu Z (2014) Cognitive deficits and decreased locomotor activity induced by single-walled carbon nanotubes and neuroprotective effects of ascorbic acid. *International Journal of Nanomedicine*; 9: 823–839
149. Llorente IL, Perez-Rodriguez D, Martinez-Villayandre B, Dos-Anjos S, Darlison MG, Poole AV, Fernandez-Loper A (2013) GABA-A receptor chloride channels are involved in the neuroprotective role of GABA following oxygen and glucose deprivation in the rat cerebral cortex but not in the hippocampus. *Brain research.* 1533, 141-151.
150. Lucas DR, Newhouse JP (1957) The toxic effect of sodium L-glutamate on the inner layers of the retina. *AMA.* 58:193–201.
151. Lundervold AJ, Reinvang I, Lundervold A (1994) Characteristic patterns of verbal memory function in patients

- with Huntington's disease. *Scand J Psychol*; 35: 38-47.
152. Lynn A. Raymond¹, Véronique M. André, Carlos Cepeda, Clare M. Gladding, Austen J. Milnerwood¹, and Michael S. Levine (2011) Pathophysiology of Huntington's Disease: Time-Dependent Alterations in Synaptic and Receptor Function. *Neuroscience*. 15; 198: 252–273.
153. Macdonald RL, Olsen RW (1994) GABA-A receptor channels. *Ann. Res. Neurosci*; 17: 569-602.
154. Macdonald RL, Rogers CJ, Twyman ER (1989) Kinetic properties of the GABAA receptor main conductance state of mouse spinal cord neurones in culture. *J Physiol (Lond)* 419: 479–499.
155. Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM (1986) Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. *Science* 232: 1004–1007.
156. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trotter Y, Leach H, Davies SW, Bates GP (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. *Cell*; 87:493-506.
157. Maragos WF, Tillman PA, Jakel RJ (1999) Chloryline and deprenyl attenuate striatal malonate and 3-nitropropionic acid. *Brain Research*; 834: 168-172.
158. Marti M, Mela F, Ulazzi L, Hanau S, Stocchi S, Paganini F, Beani L, Bianchi C, Morari M (2003) Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid. Implications for Huntington's disease. *Eur. J. Neurosci*; 18: 759-767.
159. Maxima PE, Veltri RW (1988) *FASEB*, 2, A370.
160. Menalled L, El-Khodori BF, Patry M, Suarez-Farinas M, Orenstein SJ, Zahasky B, Leahy C, Wheeler V, Yang XW, Mac Donald M, Morton AJ, Bates G, Leeds J, Park L, Howland D, Signer E, Tabina A, Brunner D (2009) Systematic behavioral evaluation of Huntington's disease transgenic and Knock in mouse models. *Neurobiol Dis*; 35: 319-336.
161. Menalled LB, Chesselet MF (2002) Mouse models of Huntington's disease. *Trends Pharmacol Sci*; 23: 32-39.
162. Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF, (2003) Time course early motor and Neuropathological anomalies in a Knock-in mouse model of Huntington's disease with 140 CAG repeat. *J Comp Neurol*; 465:11-26.
163. Mende-Mueller LM, Toneff T, Hwang SR, Chesselet MF, Hook VY (2001) Tissue- specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum. *J Neurosci*; 21: 1830-7.
164. Metzler M (2001) HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2. *J Biol Chem*; 276: 39271-6.
165. Miller JP, Holcomb J, Al-Ramahi I, de Haro M, Gafni J, Zhang N (2010) Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease. *Neuron*; 67: 199–212.

166. Mok Y, Lee SJ, Kim MS, Cui W, Moon YM, Jee SH (2012) Serum uric acid and chronic kidney disease: The Severance cohort study. *Nephrol. Dial. Transplant.* 27:1831-1835.
167. Moncada S, Bolanos JP (2006) Nitric acid, cell bioenergetics and neurodegeneration. *J. Neurochem*; 97: 1676-1689.
168. Montilla P, Tunez I, Munoz MC, Salcedo M, Feijoo M, Munoz-Castaneda JR, Bujalance I (2004) Effect of glucocorticoids on 3-nitropropionic acid induced oxidative stress in synaptosomes. *Eur. J. Pharmacol*; 488: 19-25.
169. Moretti M, Ardrccolla, Balen GDO, das Santos DB, Budni J, de Freitas AE, Farina M, Rodrigues ALS (2012) Ascorbic acid treatment similarly to fluoxetine, reverse depressive like behavior and brain oxidative damage induced by chronic unpredictable stress. *Journal of psychiatric research*; 46:331-340.
170. Morgana Moretti, Ardrccolla, Grasiela de oliveira Balen, Danubin Bonfanti das Santos, Josiane Budni, Aariara Espindola de Freitas, Marcelo Farina, Ana Lucia Severo Rodrigues (2012) Ascorbic acid treatment similarly to fluoxetine, reverse depressive like behavior and brain oxidative damage induced by chronic unpredictable stress. *Journal of psychiatric research*; 46:331-340.
171. Morris RG (1984) Development of a water maze procedure for studying spatial learning in the rat. *J Neurosci Methods*, 11: 47-60.
172. Munoz-Sanjuan I, Bates GP (2011) The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. *J Clin Invest*; 121: 476-483.
173. Myung SK, Ju W, Cho B, Oh SW, Park SM (2013) Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease. *Systematic review and meta analysis of randomised controlled trials. BMJ*; 346: f10.
174. Naarding P, Kremer HPH, Zitman FG (2001) Huntington's disease: a review of the literature on prevalence and treatment of neuropsychiatry phenomena. *Eur Psychiatry*; 16: 439-445.
175. Nicholson LF, Faull RL, Waldvogel HJ, Dragunow M (1995) GABA and GABA A receptor changes in the substantianigra of the rat following quinolinic acid lesions in the striatum closely resemble Huntington's disease. *Neuroscience*; 66:507-521.
176. Noda T, Fujita N, Yoshimori T (2009) The late stages of autophagy: how does the end begin? *Cell Death Differ*; 16: 984-990
177. Novelli A, Reilly A, Lysk PG, Henneberry R (1988) Glutamate becomes neurotoxic via the Nmethyl-D-aspartate receptor when intracellular energy levels are reduced. *Brain Res*; 451:205-212.
178. Nucifora FC (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. *Science*; 291: 2423-8.
179. Odigie IP, Okpoko FB & Ojobor PD (2007) Antioxidant Effects of Vitamin C and E on Phenylhydrazine-Induced Haemolysis in Sprague Dawley Rats: Evidence for A better Protection by Vitamin E. *The Nigerian Postgraduate Medical Journal*, 14(1): 1-7.

180. Ona V (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. *Nature*; 399: 263-7.
181. Ozkanlar S, Akcay F (2012) Antioxidant vitamins in atherosclerosis animal experiments and clinical studies. *Adv Clin Exp*, 21, 1, 115-123.
182. Paddayatti SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ and Levine M (2006) Intravenously administered vitamin C as cancer therapy: three cases. *Can Med Assoc J*. 174: 937-942.
183. Pang Z, Geddes JW (1997) Mechanisms of cell death induced by the mitochondrial toxin 3-nitropropionic acid: Acute excitotoxic necrosis and delayed apoptosis. *J Neurosci* 17:3064-3073.
184. Panov AV (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. *Nat Neurosci*; 5: 731-6.
185. Parle M, Singh N (2007) Memory deficits by atorvastatin and simastation in rats. *Yakugaku Zasshi*, 127:pp. 1123-1137.
186. Paulsen JS, Conybeare RA (2005) Cognitive changes in Huntington's disease. *Adv Neurol*.96: pp; 209-225.
187. Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance K, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M (2008) The predict HD investigators and coordinators of the Huntington's study group. Detection of Huntington's disease decades before diagnosis. The predict HD study. *J Neurol Neurosurg Psychiatry*; 79: 874-880.
188. Paulsen JS, Nehl C, Hoth KF (2005) Depression and stages of Huntington's disease. *J Neuropsychiatry Clin Neurosci*; 17: 496-502.
189. Penney JB, Young AB (1982) Quantitative autoradiography of neurotransmitter receptors in Huntington disease, *Neurology*, 32, 1391-1395.
190. Perez – Severiano F, Escalante B, Vergara P, Rios C, Segovia J (2002) Age-dependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the huntington's disease mutation. *Brain Res*; 951(1): 36-42.
191. Perez-De La Cruz V, Santamaria A (2007) Integrative hypothesis for Huntington's disease: A brief review of experimental evidence. *Physiol Res*; 56: 513-526.
192. Petersén A, Mani K & Brundin P (1999). Recent advances on the pathogenesis of Huntington's disease. *Exp Neurol*; 157: 1-18.
193. Pirker S, Schwarzer C, Wieselthaler A, Sieghart W & Sperk G (2000) GABAA receptors, immunocytochemical distribution of 13 subunits in the adult rat brain. *Neuroscience*, 101, 815-850.
194. Polidori MC, Mecocci P, Browne SE, Senin U, Beal MF (1999) Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex. *Neurosci Lett*; 272(1): 53-56.
195. Portera –Cailliau C, Hedreen JC, Price DL, Koliatsos VE (1995) Evidence for apoptotic cell death in Huntington's disease and excitotoxic animal models. *J Neurosci*; 15:3775-3787.

196. Pouladi MA, Xie Y, Skotte NH, Ehrnhoefer DE, Graham RK, Kim JE et al. (2010) Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. *Hum Mol Genet*; 19: 1528–1538.
197. Puneet K, Padi S. S. V, Naidu P. S, Kumar A (2007) 3-nitropropionic acid induced neurotoxicity: an animal model for huntington's disease, *Pharmacology Division*, 41-47
198. Puneet Kumar, Harikesh Kumar, Anil Kumar and Ashok Goyal (2010) 3-Nitropropionic acid induced neurotoxicity as an experimental model of Huntington's disease: possible behavioral, biochemical and cellular alterations. *J Pharm Educ Res*; 1: 26-35.
199. Qin ZH, Zhen LGU (2004) Huntingtin processing in pathogenesis of Huntington's disease. *Acta Pharmacol Sin*; 25: 1243-1249.
200. Qrbeck AL (1959) An early description of Huntington's chorea. *Medical History*; 3: 165-168.
201. Quarrell WJ, Brewer HM, Squitieri F, Barker RA (2009) Juvenile huntington's disease and other trinucleotide repeat disorder. *Oxford university Press, USA edition*.
202. Rangone H, Humbert S, Saudou F (2004) Huntington's disease: how does huntingtin, an anti-apoptotic protein, become toxic? *Pathol Biol (Paris)*; 52: 338-42.
203. Raymond LA, André VM, Cepeda C, Gladding CM, Milnerwood AJ, Levine MS (2011) Pathophysiology of Huntington's Disease: Time-Dependent Alterations in Synaptic and Receptor Function. *Neuroscience*. 15; 198: 252–273.
204. Rebec GV, Pierce RC (1994) A vitamin as neuromodulator: ascorbate release into the extracellular fluid of the brain regulates dopaminergic and glutamatergic transmission. *Prog. Neurobiol.* 43, 537–565
205. Reddy HP, Maya W, Danilo AT (1999) Recent advances in understanding the pathogenesis of Huntington's disease. *Trends in Neuroscience*; 22: 248- 254.
206. Riberio CA, Grando V, Dutra Filho CS, Wannmacher CM, Wajner M (2006) Evidence that quinolinic acid severely impairs energy metabolism through activation of NMDA receptors in striatum from developing rats. *J Neurochem*; 99: 1531-1542.
207. Rigamonti D et al. (2000) Wild-type huntingtin protects from apoptosis upstream of caspase- 3. *J Neurosci*; 20: 3705-13.
208. Roses HD, Salat DH, Lee SY (2008) Complexity and heterogeneity: what drives the non-changing brain in Huntington's disease. *Ann NY Acad Sci*; 1147: 196-205.
209. Rubinsztein DC (1996) Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. *Am J Hum Genet*; 59: 16-22.
210. Rubinsztein DC (2002) Lessons from animal models of Huntington's disease. *Trends Genet*; 18: 202-9.
211. Rupprecht R (2003) Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties.

- Psychoneuroendocrinology* 28: 139–168.
212. Sanchez I (1999) Caspase-8 is required for cell death induced by expanded polyglutamine repeats. *Neuron*; 22: 623-33.
213. Sawa A, Tomoda T, Bae BI (2003) Mechanisms of neuronal cell death in Huntington's disease. *Cytogenet Genome Res*; 100: 287-295.
214. Schwarcz R, Foster AC, French ED, Whetsell WO Jr, Köhler C (1984) Excitotoxic models for neurodegenerative disorders. *Life Sci*; 35: 19–32.
215. Schwarcz R, Okuno E, White RJ, Bird ED, Whetsell WO Jr (1988) 3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington's disease victim. *Proc Natl Acad Sci USA*; 85:4079-4081.
216. Schwarzer et al (2001) Distribution of GABA-A receptor subunits in the brain; *J. Comp Neurol*; 433:526.
217. Seib PA, Tolbert BM, Eds IN, Washington DC (1982) ascorbic acid chemistry, metabolism and uses. American chemical Society.
218. Shahidi S, Komaki A, Mahmoodi M, Atrvash N, Ghodrati M (2008) Ascorbic acid supplementation could affect passive avoidance learning and memory in rat. *Brain Res Bull*; 76(1-2):109-13.
219. Shannon (2011) A randomized controlled trial. *Neurology*; 66: 366-372.
220. Sharaf A, Gomaa A (1972) Progesterone-like effect of vitamins. *Plant Foods Hum Nutr*. 21: 159–64.
221. Sharma Manisha, Kumar Sunil, Sharma Nidhi (2012) A review : animal models for Huntington's disease. *IRJP*, 3(10).
222. Shear D, Dong J, Hail-Creguer KL, Bazzet TJ, Albin RL, Dumbar GL (1998) Chronic administration of quinolinic acid in the rat striatum causes apatial learning deficits in a radial arm maze task. *Exp Neurol*; 150:305-311.
223. Sieghart W (1995) Structure and pharmacology of gamma-aminobutyric acid A receptor subtypes. *Pharmacol Rev*; 47(2):181–234.
224. Sieghart W, Sperk G (2012) Subunit composition, distribution and Function of GABA-A receptor subtypes. *Current topics in medicinal chemistry*, 2, 785-816.
225. Starr PA, Kang GA, Heath S, Shimamoto S, Turner RS (2008) Pallidal neuronal discharge in Huntington's disease: support for selective loss of striatal cells originating the indirect pathway. *Exp Neurol*. 211:227–233.
226. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL0 (2001) Histone deacetylase inhibitors arrest polyglutamine dependent neurodegeneration in *Drosophila*. *Nature*; 413: 739–743.
227. Storgaard G, Kornblit BT, Zimmer J, Gramsbergen JB (2000) 3-nitropropionic acid neurotoxicity in organotypic striatal and cortico striatal slice cultures is dependent on glucose and glutamate. *Exp. Neurol*; 164: 227-235.
228. Stout JC, Jones R, Labuschagne I (2012) Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early huntington's disease. *J. Neurosury psychiatry*. 83: pp; 687-694.

229. Sugars KL, Rubinsztein DC (2003) *Transcriptional abnormalities in Huntington disease. Trends Genet*; 19: 233-8.
230. Suke SG, Shukla A, Mundhada D, Banerjee BD, Mediratta PD (2013) *Effects of phosphamidon on cognition and oxidative stress and chlorodiazepam in rats. Pharmacology Biochemistry and Behaviour*, vol 103, issue 3, pp, 637-642.
231. Sullinan PG, Dragicevic NB, Deng JH, Bavi Y, Dimayuga E, Ding Q, Chem Q, Bruce-Keller AJ, Keller JN (2004) *Proteasome inhibition alters neuronal mitochondrial homeostasis and mitochondrial turnover. J. Biol Chem.* 279: 20699-20707.
232. Tabrizi SJ, Cleeter M and Xuereb J (1999) *Annal. Neurol*; 45: 25-32.
233. Tabrizi SJ, Workman J, Mangiarini L, Mahal A, Bates G, Cooper JM, Schapira AH (2000) *Mitochondrial dysfunction and free radical damage in Huntington's R6/2 transgenic mouse. Ann. Neurol*; 47: 80-86.
234. Tandon V, Gupta RK (2005) *Effect of Vitex negundo on oxidative stress. Indian J Pharm.* 37:38-40.
235. The Huntington's Disease Collaborative Research Group (1993) *A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell*; 72: 971-83.
236. The Predict-HD investigators and coordinators of the Huntington study Group. *Detection of Huntington's disease decades before diagnosis. The Predict -HD study. J Neuronal Neurosurg Psychiatry*; 79:310-880.
237. Thomas, LB et al. (1995) *DNA endlabeling (TUNEL) in Huntington's disease and other neuropathological conditions. ExpNeurol*; 133: 265-72.
238. Tian N, Moore RS, Braddy S, Rose RA, Gu JW, Hughson MD, Manning RD (2007) *Interactions between oxidative stress and inflammation in salt-sensitive hypertension. Am. J. Physiol. Heart Circ. Physiol.* 293:3388-3395.
239. Tolsa JF, Gao Y, Raj JU (2000) *Developmental change in magnesium sulfate-induced relaxation of rabbit pulmonary arteries. JAppl transgenic mouse model of Huntington disease. Nat Med*; 6: 797-801.
240. Tsao CS (1997) *in an overview of ascorbic acid chemistry and biochemistry vitamin C in health and disease. Antioxids. Health and Dis.* 5, pp.25-58.
241. Tunez I, Collado JA, Medina FJ, Pena J, Munoz MC, Jimena I, Franco F, Rueda I, Feijoo M, Muntane J, Montilla P (2006a) *17 Beta estradiol may effect vulnerability of stratum in a 3-nitropropionic acid induced experimental model of Huntington's disease in ovariectomized rats. Neurochem. Int*; 48: 367-373.
242. Tunez I, Drucker Colin R, Jimena I, Medina FJ, Munoz MC, Pena J, Montilla P (2006b) *Transcranial magnetic stimulation attenuates cell loss and oxidative damage in the striatum induced in the 3-Nitropropionic model of Huntington's disease. J. Neurochem*; 97: 619-630.
243. Tunez I, Feijoo M, Collado JA, Medina FJ, Pena J, Munoz MC, Jimena I, Franco F, Rueda I, Muntane J, Montilla P (2007) *Effect of testosterone on oxidative stress and cell damage induced by 3-nitropropionic acid in striatum of ovariectomized rats. Life Sci*; 80:1212-1227.

244. Tunez I, Montilla P, Munoz MC, Feijo M, Salcedo M (2004b) protective effect of melatonin on 3-nitropropionic acid induced oxidative stress in synaptosomes in an animal model of huntington's disease. *J. Pineal Res*; 37: 252-256.
245. Tunez I, Montilla P, Munoz MC, Feijoo M, Salcedo M (2004a) protective effect of nicotine on 3-nitropropionic acid induced oxidative stress in synaptosomes. *Eur. J. Pharmacol*, (504), 169-175.
246. Tunez I, Montilla P, Del Carmen –Munoz M, Feijo M (2004) protective effect of melatonin on 3-nitropropionic acid induced oxidative stress in synaptosomes in an animal model of Huntington's disease. *J Pineal Res* (37) 252-256.
247. Ueno S, Bracamontes J, Zorumski C, Weiss DS, Steinbach JH (1997) Bicuculline and gabazine are allosteric inhibitors of channel opening of the GABAA receptor. *J Neurosci* 17: 625–634.
248. Van Raamsdonk JM, Pearson J, Slow EJ, Hossain SM, Leavitt BR, Hayden MR (2005) Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. *J Neurosci*; 25: 4169- 4180.
249. Veltri RW, Fodorg G, Liu CM, Woolverton CJ, Baseler MWJ (1986) *Biol Modifiers*, 5,444-61.
250. Viguet-Carrin S, Garnero P, Delmas PD (2006) The role of collagen in bone strength. *Osteoporos Int*; 17: 310-336.
251. Vis JC (2005) Expression of apoptosis-related markers in human HD brains. *Acta Neuropathol*; 109: 321-8.
252. Vissers MCM, Bozond SM, Pearson JF, Braithwaite LJ (2011) Dietary ascorbate intake effects steady state tissue concentration in vitamin c deficient mice: tissue deficiency after time intake and superior bioavailability from source (Kiwifruit). *Am J Clin Nut*, vol 93 (2), pp.292-301.
253. Vonsattel JP, DiFiglia M (1998) Huntington disease. *J NeuropatholExpNeurol*; 57: 369-84.
254. Vonsattel J, Lianski M (2004) Huntington's disease. In *The Neuropathology of Dementia* (eds. Eisri MM, Lee VM, Trojanowski JQ), Cambridge University Press, Cambridge, UK, 376-401.
255. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr (1985) Neuropathological classification of Huntington's disease. *J NeuropatholExp Neurol*. 44:559–577.
256. Sieghart W & Sperk G (2012) Subunit composition, distribution and Function of GABA-A receptor subtypes. *Current topics in medicinal chemistry*, 2, 785-816.
257. Waelter S (2001) The huntingtin interacting protein HIP1 is a clathrin and alpha- adaptin-binding protein involved in receptor-mediated endocytosis. *Hum Mol Genet*; 10: 1807-17.
258. Waldvogel HJ, Thu D, Hogg V, Tippett L, Faull RLM (2012) Selective neurodegeneration, neuropathology and symptoms profiles in Huntington's disease. *Tandem Repeat Polymorphism: Genetic Plasticity, Neural Diversity and disease*, edited by Anthony J. Hannan Landes Bioscience and Springer science, 141-152.
259. Wallace MJ, Newton PM, Oyasu M, McMahon T, Chou WH, Connolly J et al. (2007) Acute functional tolerance to ethanol mediated by protein kinase Cepsilon. *Neuropsychopharmacology*, 32: 127–136.

260. Wallace RH, Marini C, Petrou S, Harkin LA, Bowser DN, Panchal RG (2001) Mutant GABAA receptor gamma 2-subunit in childhood absence epilepsy and febrile seizures. *Nature Genetics*, 28: 49-52.
261. Wallace RH, Marini C, Petrou S, Harkin LA, Bowser DN, Panchal RG (2001) Mutant GABAA receptor gamma 2-subunit in childhood absence epilepsy and febrile seizures. *Nature Genetics*, 28: 49-52.
262. Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E (2003) Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. *Proc Natl Acad Sci USA*; 100: 10483–10487.
263. Wellington CL, Brinkman RR, O'Kusky JR, Hayden MR (1997) Toward understanding the molecular pathology of Huntington's disease. *Brain Pathol*; 7: 979- 1002.
264. Wellington CL, Leavitt BR, Hayden MR (2000) Huntington disease: new insights on the role of huntingtin cleavage. *J Neural Transm Suppl*; 58: 1-17.
265. Williams MJ, Sutherland WH, McCormick MP, de Jong SA, McDonald JR, Walker RJ (2001) Vitamin C improves endothelial dysfunction in renal allograft recipients. *Nephrol. Dial. Transplant.* 16:1251-1255.
266. Wimalazena, Dabroust Kanral, Hinterleitner Silver (1989) Application of a simultaneous assay of ascorbic acid, dehydroascorbic acid and ascorbic sulphate in biological materials, *Analyst*, 114,83-87.
267. Wu D, Lu J, Zhang Y (2013) Ursolic acid improves domoic acid-induced cognitive deficits in mice. *Toxicol Appl Pharmacol.* 271:127–136.
268. Xavier SM, Barbosa CO, Barros DO, Silva RF, Oliveira AA, Freitas RM (2007) Vitamin C antioxidant effects in hippocampus of adult rats after seizures and status epilepticus induced by pilocarpine. *Neurosci Lett*;420:76–9.
269. Young AB, Helen S, Ciliax BJ, Penny JB (1984) GABA and Benzodiazepines receptors in basal ganglia function. *Neuroscience Letters, Elsevier Scientific Publishers Ireland Ltd.* 47: 361-367.
270. Young Anne B, Helen S, Ciliax Brian J and Penny John B (1984) GABA and Benzodiazepines receptors in basal ganglia function. *Neuroscience Letters, Elsevier Scientific Publishers Ireland Ltd.* 47: 361-367.
271. Zamani M & Soleimani M & F. Golab F. Mohamadzadeh M. Mehdizadeh M. Katebi M (2013) NeuroProtective effects of adenosine receptor agonist coadministration with ascorbic acid on CA1 hippocampus in a mouse model of ischemia reperfusion injury, *Metab Brain Dis*: 28:367–37.
272. Zamani M, Soleimani M, Golab F, Mohamadzadeh M, Mehdizadeh M, Katebi M (2013) NeuroProtective effects of adenosine receptor agonist coadministration with ascorbic acid on CA1 hippocampus in a mouse model of ischemia reperfusion injury, *Metab Brain Dis*: 28:367–37.
273. Zhou R, Yazdi AS, Menu P, Tschopp J (2011) A role for mitochondria in NLRP3 inflammasome activation. *Nature*; 469: 221–225.
274. Zhu S, Zhang Y, Bai G, Li H (2011) Necrostatin-1 ameliorates symptoms in R6/2 transgenic mouse model of Huntington's disease. *Cell Death Dis*; 2: e115.

275. Zola-Morgan S, Squire LR, Amaral DG (1986) Human amnesia and the medial temporal region: enduring memory impairment following a bilateral lesion limited to field CA1 of the hippocampus. *J Neurosci.* 6: 2950–2967.
276. Zuccato C (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. *Science*; 293: 493-8.
277. Zuccato C, Cattaneo E (2007) Role of brain derived neurotrophic factors in Huntington's disease. *Prog Neurobiol*; 81 (5-6): 294-330.